There is no effective FDA-approved medication for adenoviral conjunctivitis currently available.

Increased activity against Simplex Virus, S. aureus, S. mannosiae, H. influenzae and C. albicans.

Staphylococcus aureus

Cytotoxicity Assay:

Modified Minimum Bactericidal Concentration (MBC) and Minimum Fungicidal Concentration (MFC) assays.

Antimicrobial Activity against

Conclusions

Materials and Methods

We present novel, fast-acting, broad-spectrum Aganocide® compounds with good solution stability and broad-spectrum activity against viral, bacterial and fungal ophthalmic pathogens. The broad-spectrum antimicrobial compounds with increased virucidal activity and a better improved cytotoxicity profile compared to NVC-422. The acyclic hydrophilic compound NVC-727 (3-(dichloroamino)-3-methylbutylsulfonyl)ethanesulfonic acid) has similar microbicidal activity but a further increased activity against C. albicans combined with a favorable cytotoxicity, bactericidal and virucidal profile.

Purpose: We present novel, fast-acting, broad-spectrum Aganocide® compounds with good solution stability and broad-spectrum activity against viral, bacterial and fungal ophthalmic pathogens. The broad-spectrum antimicrobial compounds with increased virucidal activity and a better improved cytotoxicity profile compared to NVC-422. The acyclic hydrophilic compound NVC-727 (3-(dichloroamino)-3-methylbutylsulfonyl)ethanesulfonic acid) has similar microbicidal activity but a further increased activity against C. albicans combined with a favorable cytotoxicity, bactericidal and virucidal profile.

Table 1: Virucidal Activity against Adenovirus 5 and HSV-1

Table 2: Antimicrobial Activity against S. aureus, E. coli and C. albicans

Conclusions Th e Aganocide® compounds NVC-422 and NVC-727 are, broad-spectrum, fast-acting antimicrobial agents with a good safety profile with a new mechanism of action.

Conclusions

Materials and Methods

We present novel, fast-acting, broad-spectrum Aganocide® compounds with good solution stability and broad-spectrum activity against viral, bacterial and fungal ophthalmic pathogens. The broad-spectrum antimicrobial compounds with increased virucidal activity and a better improved cytotoxicity profile compared to NVC-422. The acyclic hydrophilic compound NVC-727 (3-(dichloroamino)-3-methylbutylsulfonyl)ethanesulfonic acid) has similar microbicidal activity but a further increased activity against C. albicans combined with a favorable cytotoxicity, bactericidal and virucidal profile.

Table 1: Virucidal Activity against Adenovirus 5 and HSV-1

Table 2: Antimicrobial Activity against S. aureus, E. coli and C. albicans

Conclusions

Materials and Methods

We present novel, fast-acting, broad-spectrum Aganocide® compounds with good solution stability and broad-spectrum activity against viral, bacterial and fungal ophthalmic pathogens. The broad-spectrum antimicrobial compounds with increased virucidal activity and a better improved cytotoxicity profile compared to NVC-422. The acyclic hydrophilic compound NVC-727 (3-(dichloroamino)-3-methylbutylsulfonyl)ethanesulfonic acid) has similar microbicidal activity but a further increased activity against C. albicans combined with a favorable cytotoxicity, bactericidal and virucidal profile.

Table 1: Virucidal Activity against Adenovirus 5 and HSV-1

Table 2: Antimicrobial Activity against S. aureus, E. coli and C. albicans